Cardiovascular autonomic neuropathy often goes unrecognized. We present a case of a 22-year-old man with multiple manifestations of this disease, including weakness, dizziness, fatigue, tachycardia, abnormal QTc, and orthostasis, which occurred 2 years after his type 1 diabetes diagnosis. He exhibited parasympathetic denervation with resting tachycardia and exercise intolerance but also had evidence of orthostatic hypotension, which suggests sympathetic denervation. He did not have complete cardiovascular autonomic reflex testing, which would have been helpful, but improved with aggressive diabetes treatment and the increase of beta-blockade. It is important to identify these patients to understand their signs and symptoms and consider appropriate therapies. C ardiovascular autonomic neuropathy (CAN) is a serious and common complication of diabetes mellitus (DM) that is often not recognized. Diabetes mellitus aff ects more than 26 million people in the United States. Prevalence rates of CAN increase with age and duration of DM. Th e Diabetes Control and Complication Trial reported rates as high as 35% in type 1 DM and 44% in type 2 DM, with a prevalence rate of up to 60% in longstanding diabetics ( 1 ). Th e presence of CAN is associated with increased cardiovascular mortality and is the cause of cardiac dysfunction and multiple clinical symptoms, including resting tachycardia, exercise intolerance, postural hypotension, silent ischemia, cardiomyopathy, and perioperative instability ( 1 -4 ).
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CASE REPORT
A 22-year-old African American man with a 2-year history of type 1 DM presented to the clinic with complaints of fatigue, decreased exercise tolerance, palpitations, and persistent tachycardia. He was 6' tall and 147 lb. His blood pressure and heart rate recorded supine, sitting, and standing after 3 . Th e echocardiogram demonstrated an ejection fraction of 45% to 50%, mild septal bounce, and left ventricular diastolic abnormality. A cardiac nuclear study reported an ejection fraction of 37% with global hypokinesis. His hemoglobin A1c level was 10.7%, with a history of poorly controlled blood sugars. His medications at the time of the clinic visit included metoprolol succinate 50 mg daily, insulin therapy, and gabapentin. Once CAN was diagnosed, the patient improved with aggressive treatment of his diabetes, which lowered his hemoglobin A1c to <7, and the increase of beta-blockade.
DISCUSSION
CAN is the impairment of cardiovascular autonomic control in the setting of diabetes after exclusion of other causes. Ewing et al ( 5 ) recommend fi ve simple tests, the cardiac autonomic refl ex tests, to establish the diagnosis: 1) HRV with deep breathing; 2) HRV lying to standing; 3) the Valsalva maneuver; 4) postural fall in blood pressure; and 5) blood pressure response to sustained handgrip. A single abnormal test may indicate early CAN, and three positive tests are recommended for a defi nite diagnosis ( 3 ).
In early subclinical CAN, the cardiovascular autonomic refl ex tests may not be able to detect any abnormalities; however, CAN is also detected by abnormal plasma catecholamine and cardiac imaging ( 1 , 6 , 7 ) . Scintigraphy has been vital in diagnosing subclinical CAN ( 3 ). Diastolic dysfunction is observed with the echocardiogram, while cardiac magnetic resonance imaging can detect early stages of CAN via myocardial torsion ( 8 ). Pappachan et al found a connection between CAN and prolongation of QTc and suggested that QTc can be used to diagnose CAN ( 9 ). However, Valensi et al found that QTc was not signifi cantly diff erent between diabetic patients with and without CAN and control patients ( 10 ) .
Th e progression of CAN usually begins with parasympathetic denervation, followed by sympathetic tone enhancement Baylor University Medical Center Proceedings Volume 29, Number 2 and eventually sympathetic denervation ( 1 , 11 , 12 ) ; therefore, resting tachycardia is often the presenting sign (ranging from 100 to 130 bpm). As CAN progresses in severity, there is a decrease in heart rate. Patients with subclinical CAN will have abnormalities in HRV, which is followed by changes in barorefl ex sensitivity ( 3 , 13 ) . With advanced CAN, sympathetic denervation along with impaired barorefl ex sensitivity and decreased norepinephrine response to change in posture will result in orthostasis ( 3 ) . Th e pathological mechanism of CAN remains uncertain but is likely multifactorial ( 14 ) . What seems to be fundamental in the development and progression of CAN is hyperglycemia and its activation of multiple metabolic and/or redox pathways. Th is, in conjunction with reduced blood fl ow to nerve fi bers, contributes to the disorder ( 1 ) . Myocardial blood fl ow activity in response to sympathetic stimulation is signifi cantly impaired after longstanding type 1 DM and may contribute to the eventual development of myocardial injury ( 15 ) .
CAN prevalence increases with age and a longer duration of diabetes. However, in select patients, it occurs in youth early in the course of the disease ( 15 ) . CAN is linked to mortality risk, as shown by a metaanalysis of 15 diff erent studies ( 16 ) . In the EURODIAB Prospective Complications Study, albuminuria and peripheral and autonomic neuropathy had a strong association with mortality in patients with type 1 DM ( 17 ) .
Th ere are limited therapeutic approaches to prevent or reverse CAN, and this may be due to the fact that the exact mechanisms behind the development of CAN are not understood. Lifestyle modifi cations have improved moderate CAN ( 1 ). Weight loss in obese diabetics and aerobic exercise for patients with both type 1 and type 2 DM improved HRV and cardiac autonomic functionality ( 1 , 3 ) . Early and comprehensive glycemic control is thought to prevent diabetic complications and potentially reverse CAN symptoms ( 1 , 3 ) .
One therapy that may be eff ective in the management of CAN is the beta-blocker bisoprolol, which was shown to increase HRV related to parasympathetic activity in heart failure ( 18 ). Gottlieb et al noted that post-myocardial infarction diabetic patients had a 36% reduction in mortality with the use of beta-blockers ( 19 ) . Th e use of angiotensin-converting enzyme inhibitors hinders downstream sympathetic outfl ow; 1-year use of quinapril resulted in some benefi t for treating CAN ( 20 ) , while a year of trandolapril resulted in no benefi ts of autonomic function or neuropathy symptoms in patients with CAN ( 21 ) . Diabetic patients with neuropathy were treated for a year with an aldose reductase inhibitor (zopolrestat) and showed improved resting and exercise left ventricular ejection fractions, cardiac output, and stroke volume ( 22 ) .
Orthostasis can be treated both pharmacologically and with lifestyle changes. Midodrine and 9-alpha-fl ourohydrocortisone improved systolic blood pressure upon standing ( 23 , 24 ) . Somatostatin and somatostatin analogues (octreotide) increased blood pressure in patients with autonomic neuropathy ( 25 ) . Pyridostigmine bromide improved symptoms without worsening supine hypertension ( 26 ) . CAN is underrecognized in diabetic patients. Autonomic testing is a helpful and cost-eff ective aid to diagnosis. CAN is a common disorder that is not only associated with DM but also occurs in patients with malignancy, autoimmune disorders, Parkinson's disease, and a number of other neurologic and medical disorders. It is important to identify these patients to understand their signs and symptoms and consider appropriate therapies.
